Repare Therapeutics’ Post

View organization page for Repare Therapeutics, graphic

14,640 followers

4mo

We are thrilled to share that the FDA granted Fast Track designation to the lunresertib-camonsertib combination for the treatment of platinum-resistant ovarian cancer. Learn more here: https://lnkd.in/e5n8Acxn #precisiononcology #syntheticlethality #fasttrackdesignation #ovariancancer

11 Comments

Maria Koehler MD PhD

Chief Medical Officer at Repare Therapeutics

4mo

So satisfying to work with a great team that delivers great medicines to offer promise to patients- the promise will soon become a reality …..that’s why we all are doing this work = pleasure

4 Reactions

Gagan Kukreja

Associate Director, Medicinal Chemistry, SynVent IDD, Syngene

4mo

Really a ground breaking discovery. And probably this is just a start. Besides ATR, I am sure lunresertib (RP-6306) first-in-class, oral PKMYT1 inhibitor will do equally well or even better in the ongoing Phase 1 in combination with Wee1 inhibitor from Debiopharm. Again credit goes to Repare! With efficacy granted, what remains to be seen is whether FDA would grant Fast Track designation to this PKMYT1/WEE1 combination, when both of RP-6306 and Debio-0123 are still in Phase 1 and Phase 1/2 clinical trials as standalone therapies with no prior drug approvals coming from either of the drug targets.

1 Reaction

STRAT2TACT Consulting

3mo

Wonderful news. Congratulations!

Martin Højgaard

Oncologist, Phase 1 Unit, Department of Oncology at Rigshopitalet

4mo

Great news, well deserved

1 Reaction

Patrick Montpetit

Strategic Advisor | Board Director | Private Equity Partner | International Experiences in Europe & LATAM

4mo

Great news. Well done team Repare

Jeff Bockman

EVP & Expert Advisor, Oncology, Head Center of Excellence, Lumanity, current or past Scientific/Clinical/Strategic Advisory Boards at ImmunOS, Valo Therapeutics, hC Bioscience, Pearl Bio, Skipper BioMed

3mo

Fantastic work, kudos to the Repare team.

Oksana Bovt

CEO | Investor communications | Fundraising marketing | Life sciences | Theoria Creative

4mo

This is a great achievement Steve Forte, Lloyd Mitchell Segal and Repare Therapeutics!

Demetra Georgiopoulos

Biopharmaceutical Consultant, New Product Pipeline, Portfolio & Commercial Strategy

4mo

Amazing news!

Tracy Flack Tyler, MBA

Founder and Managing Principal, Strategies for Success Int'l

4mo

Fantastic news, Lloyd! Wishing you continued success!

Rafi Hofstein

life science executive

4mo

Sensational!

See more comments

To view or add a comment, sign in

More Relevant Posts

PURE MEDICAL

4 followers
4mo
Report this post
Until now, there have been no adequate easy early screening methods or diagnostic methods for detecting pancreatic cancer. For the first time ever, we now have the opportunity to offer individuals at high risk a unique early pancreatic cancer test. https://lnkd.in/e3jqjpsU #liquidbiopsy #pancreaticcancer
Like Comment
To view or add a comment, sign in
The WISDOM Study

626 followers
9mo
Report this post
Happy New Year from the WISDOM Study! #WISDOM #Breastcancerscreening #Happynewyear! To learn more about the WISDOM Study and personalized breast cancer screening, go to thewisdomstudy.org
Like Comment
To view or add a comment, sign in
Deepasri Multispecialities Hospital

5 followers
1mo
Report this post
Be Aware of Ovarian Cancer!!! Don't ignore these subtle symptoms which could be signs of ovarian cancer, and early detection is crucial. Visit: https://lnkd.in/g-qEguz9 #deepasrihospital #deepasrimultispecialitieshospital #deepasri #ovariancancerawareness #ovariancancer #OvarianCancerAwarenessMonth #AwarenessSaves
Like Comment
To view or add a comment, sign in
Eisai Co., Ltd.

5,836 followers
1mo
Report this post
September is #OvarianCancerAwarenessMonth ! #Eisai invited 4 ovarian cancer patients for a round-table talk as part of an activity aiming to learn more about patients’ anxieties. Read more about our challenges to realize cancer treatment without suffering from side effects 👉 https://lnkd.in/gYsZNE-p #ovariancancer #hhc
Like Comment
To view or add a comment, sign in
Singapore Society of Oncology (SSO)

34 followers
1mo
Report this post
Appendix cancer, also known as appendiceal cancer, is a very rare malignant tumor that forms in the vermiform appendix. It is more common among women and those above 50 years of age. Together let’s help those in need and fight this battle together! #Appendixcancer #earlydetection #CancerAwareness #CancerTreatments #SSO #SSOSingapore #SingaporeSocietyOfOncology
Like Comment
To view or add a comment, sign in
Women's Cancer Research Foundation

176 followers
9mo
Report this post
🔬 Join us in envisioning a future with improved breast cancer screening! Our blog post examines the exciting possibilities and progress being made in the fight against breast cancer. Together, we can make a difference! Learn more at the link in the comments. #BreastCancerResearch #ScreeningAdvancements #HopeForTheFuture #CancerResearch
1 Comment
Like Comment
To view or add a comment, sign in
MediMix

1,064 followers
3mo
Report this post
🔥 ASCO 2024 Plenary: Prof Dr Christian Blank (Netherlands Cancer Institute) presents the NADINA trial results, highlighting the significant benefit of neoadjuvant immunotherapy in stage III melanoma, suggesting a new standard of care. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #Melanoma #SkinCancer #OncologyInnovation

1 Comment
Like Comment
To view or add a comment, sign in
Sonnet BioTherapeutics

1,624 followers
1w
Report this post
Let's continue to raise awareness as September ends. Together, we can make a difference in the fight against ovarian cancer. Discover how you can get involved: https://bit.ly/3YALP7u #SONN #ImmunoTherapies #Oncology #ImmuneTherapies #OvarianCancer #EndOvarianCancer
Like Comment
To view or add a comment, sign in
Omnia Korani

Passionate Medical Oncologist | Assistant Lecturer at National Cancer Institute | ESMO Certified | ESCO Graduate |ESGO member| ASCO Member | Dedicated to Improving Patient QOL and Outcomes.
4mo
Report this post
1st ADC in ovarian cancer

Targeted Oncology

54,823 followers
4mo

Mirvetuximab soravtansine monotherapy led to an objective response rate of 51.9% in heavily pretreated patients with FRα+, platinum-sensitive ovarian cancer, meeting the primary end point of the phase 2 PICCOLO trial. #GYNCSM https://lnkd.in/eJtiWjfe

Phase 2 Study of Mirvetuximab in Ovarian Cancer Meets Primary End Point
Like Comment
To view or add a comment, sign in
NCODA

15,400 followers
8mo
Report this post
Empower yourself and your loved ones in the fight against cancer! Our Oral Chemotherapy Education (OCE) sheets offer valuable insights into drugs like Adagrasib, used for treating non-small cell lung cancer with the KRAS G12C variant. Ease the journey with reliable information. Explore the Adagrasib OCE sheets and more at the link below: https://bit.ly/427mxj8 #CancerSupport #OncologyEducation
Like Comment
To view or add a comment, sign in

14,640 followers

View Profile Follow

Repare Therapeutics’ Post

More Relevant Posts

Explore topics